SYRE – spyre therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 [Yahoo! Finance]
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Spyre Therapeutics Announces Grants of Inducement Awards
Form EFFECT Spyre Therapeutics, Inc.
Form 4 Spyre Therapeutics, Inc. For: Mar 03 Filed by: Burrows Scott L
Form 4 Spyre Therapeutics, Inc. For: Mar 02 Filed by: Turtle Cameron
Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L
Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.